Acuta Capital Partners
$143M 13F equity value
30 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Acuta Capital Partners covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PRAX | PRAXIS PRECISION MEDICINES I | 82,796 | $28M | 19.3% |
| WHWK | WHITEHAWK THERAPEUTICS INC | 4,685,912 | $21M | 15.0% |
| TNGX | TANGO THERAPEUTICS INC | 390,949 | $12M | 8.5% |
| STRO | SUTRO BIOPHARMA INC | 270,251 | $9M | 6.3% |
| AVBP | ARRIVENT BIOPHARMA INC | 218,694 | $8M | 5.3% |
| FDMT | 4D MOLECULAR THERAPEUTICS INC | 507,801 | $7M | 4.7% |
| DRUG | BRIGHT MINDS BIOSCIENCES INC | 92,745 | $7M | 4.5% |
| OCUL | OCULAR THERAPEUTIX INC | 532,481 | $5M | 3.6% |
| ERAS | ERASCA INC | 265,199 | $5M | 3.4% |
| SRZN | SURROZEN INC | 173,395 | $4M | 3.1% |
Track Acuta Capital Partners's 13F portfolio: $143M in reported holdings, 30 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}